Show simple item record

dc.contributor.authorHanna, C. R.
dc.contributor.authorO'Cathail, S. M.
dc.contributor.authorGraham, J. S.
dc.contributor.authorSaunders, Mark P
dc.contributor.authorSamuel, L.
dc.contributor.authorHarrison, M.
dc.contributor.authorDevlin, L.
dc.contributor.authorEdwards, J.
dc.contributor.authorGaya, D. R.
dc.contributor.authorKelly, C. A.
dc.contributor.authorLewsley, L. A.
dc.contributor.authorMaka, N.
dc.contributor.authorMorrison, P.
dc.contributor.authorDinnett, L.
dc.contributor.authorDillon, S.
dc.contributor.authorGourlay, J.
dc.contributor.authorPlatt, J. J.
dc.contributor.authorThomson, F.
dc.contributor.authorAdams, R. A.
dc.contributor.authorRoxburgh, C. S. D.
dc.date.accessioned2022-01-11T12:00:15Z
dc.date.available2022-01-11T12:00:15Z
dc.date.issued2021en
dc.identifier.citationHanna CR, O’Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, et al. Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) Vol. 16, Radiation Oncology. Springer Science and Business Media LLC; 2021.en
dc.identifier.pmid34857017en
dc.identifier.doi10.1186/s13014-021-01941-zen
dc.identifier.urihttp://hdl.handle.net/10541/624985
dc.titleCorrection to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)en
dc.typeOtheren
dc.contributor.departmentCancer Research UK Glasgow Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Institute of Cancer Sciences, University of Glasgow, Level 0, 1053 Great Western Road, Glasgow, G12 0YN, UK.en
dc.identifier.journalRadiotherapy and Oncologyen
dc.description.noteen]
refterms.dateFOA2022-04-12T09:44:41Z


Files in this item

Thumbnail
Name:
34857017.pdf
Size:
565.7Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record